Arbutus Biopharma Corp Cash and Cash Equivalents, Period Increase (Decrease)
Arbutus Biopharma Corp (ABUS) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$5.14 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-03-05
CAD
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|
| 2012-12-31 | 37.60M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | -3.16M CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | -12.05M CAD 20-F · filed 2013-03-27 |
| 2009-12-31 | -1.82M CAD 20-F · filed 2012-03-27 |
USD
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 3 month as first filed | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-12-31 | -$5.14M 10-K · filed 2020-03-05 | |||||
| 2018-12-31 | -$17.35M 10-K · filed 2020-03-05 | |||||
| 2018-06-30 | -$2.27M 10-Q · filed 2018-08-03 | -$44.10M 10-Q · filed 2018-08-03 | -$5.03M derived: sum of 3 quarters · filed 2019-03-07 | -$14.02M derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2018-03-31 | -$41.83M 10-Q · filed 2018-05-04 | -$2.76M derived: sum of 2 quarters · filed 2019-03-07 | -$11.75M derived: sum of 3 quarters · filed 2019-03-07 | -$17.39M derived: sum of 4 quarters · filed 2019-03-07 | ||
| 2017-12-31 | $39.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $30.08M derived: sum of 2 quarters · filed 2019-03-07 | $24.44M derived: sum of 3 quarters · filed 2019-03-07 | $30.88M 10-K · filed 2019-03-07 | ||
| 2017-09-30 | -$8.99M 10-Q · filed 2017-11-02 | -$14.63M derived: sum of 2 quarters · filed 2018-08-03 | -$8.19M 10-Q · filed 2017-11-02 | -$11.40M derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-06-30 | -$5.64M 10-Q · filed 2018-08-03 | $799.00K 10-Q · filed 2018-08-03 | -$2.42M derived: sum of 3 quarters · filed 2018-08-03 | -$18.76M derived: sum of 4 quarters · filed 2018-08-03 | ||
| 2017-03-31 | $6.44M 10-Q · filed 2018-05-04 | $3.22M derived: sum of 2 quarters · filed 2018-05-04 | -$13.12M derived: sum of 3 quarters · filed 2018-05-04 | -$114.92M derived: sum of 4 quarters · filed 2018-05-04 | ||
| 2016-12-31 | -$3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$19.56M derived: sum of 2 quarters · filed 2018-03-16 | -$121.36M derived: sum of 3 quarters · filed 2018-03-16 | -$143.37M 10-K · filed 2018-03-16 | ||
| 2016-09-30 | -$16.34M 10-Q · filed 2017-11-02 | -$118.14M derived: sum of 2 quarters · filed 2017-11-02 | -$140.15M 10-Q · filed 2017-11-02 | -$154.46M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-06-30 | -$101.80M 10-Q · filed 2017-08-03 | -$123.81M 10-Q · filed 2017-08-03 | -$138.12M derived: sum of 3 quarters · filed 2018-03-16 | -$164.24M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2016-03-31 | -$22.01M 10-Q · filed 2017-05-04 | -$36.32M derived: sum of 2 quarters · filed 2018-03-16 | -$62.43M derived: sum of 3 quarters · filed 2018-03-16 | -$87.50M derived: sum of 4 quarters · filed 2018-03-16 | ||
| 2015-12-31 | -$14.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$40.43M derived: sum of 2 quarters · filed 2018-03-16 | -$65.50M derived: sum of 3 quarters · filed 2018-03-16 | $94.59M 10-K · filed 2018-03-16 | ||
| 2015-09-30 | -$26.12M 10-Q · filed 2016-11-03 | -$51.19M derived: sum of 2 quarters · filed 2016-11-03 | $108.90M 10-Q · filed 2016-11-03 | $102.91M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-06-30 | -$25.07M 10-Q · filed 2016-08-04 | $135.02M 10-Q · filed 2016-08-04 | $129.03M derived: sum of 3 quarters · filed 2017-03-22 | $121.94M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2015-03-31 | $160.09M 10-Q · filed 2016-05-04 | $154.10M derived: sum of 2 quarters · filed 2017-03-22 | $147.01M derived: sum of 3 quarters · filed 2017-03-22 | $97.92M derived: sum of 4 quarters · filed 2017-03-22 | ||
| 2014-12-31 | -$5.99M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-22 | -$13.08M derived: sum of 2 quarters · filed 2017-03-22 | -$62.17M derived: sum of 3 quarters · filed 2017-03-22 | $3.47M 10-K · filed 2017-03-22 | ||
| 2014-09-30 | -$7.09M 10-Q · filed 2015-11-05 | -$56.18M derived: sum of 2 quarters · filed 2015-11-05 | $9.46M 10-Q · filed 2015-11-05 | $42.34M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-06-30 | -$49.09M 10-Q · filed 2015-08-07 | $16.55M 10-Q · filed 2015-08-07 | $49.43M derived: sum of 3 quarters · filed 2016-03-09 | $46.53M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2014-03-31 | $65.64M 10-Q · filed 2015-05-06 | $98.52M derived: sum of 2 quarters · filed 2016-03-09 | $95.63M derived: sum of 3 quarters · filed 2016-03-09 | $92.73M derived: sum of 4 quarters · filed 2016-03-09 | ||
| 2013-12-31 | $32.88M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-09 | $29.98M derived: sum of 2 quarters · filed 2016-03-09 | $27.09M derived: sum of 3 quarters · filed 2016-03-09 | $21.69M 10-K · filed 2016-03-09 | $21.69M 6-K · filed 2014-03-06 | |
| 2013-09-30 | -$2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$5.79M derived: sum of 2 quarters · filed 2014-11-07 | -$11.19M 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | -$2.90M 10-Q · filed 2014-11-07 | -$4.39M 10-Q · filed 2014-08-14 | -$8.29M 10-Q · filed 2014-08-14 | |||
| 2013-03-31 | -$3.90M 10-Q · filed 2014-05-14 | |||||
| 2012-12-31 | $37.99M 10-K · filed 2015-03-13 | $37.99M 6-K · filed 2014-03-06 | ||||
| 2011-12-31 | -$3.38M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |